Shares of other companies:
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
April 17, 2024 Bitcoin Halving 2024: Market Impact Predictions
April 14, 2024 Markets Rattle: Iran-Israel Conflict and Economic Data Ahead
Apple’s Technical Climb To $240 By Year-End
April 15, 2024
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading
Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
ALKS Stock News and Mentions of Alkermes plc Stocktwits
Updated: April 20, 2024 (09:15)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Alkermes Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Alkermes plc (ALKS).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Alkermes stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Alkermes plc (ALKS)
April 17, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Alkermes ( ALKS ) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Somewhat-Bullish
April 16, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In Article Trend: Bullish
April 11, 2024 (14:15) / "Zacks Commentary" (by Zacks Equity Research)
Alkermes' ( ALKS ) ALKS 2680 Betters Wakefulness in Phase Ib Study
Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.
In Article Trend: Somewhat-Bullish
April 10, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Why Alkermes ( ALKS ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In Article Trend: Bullish
April 9, 2024 (18:23) / "Benzinga" (by Vandana Singh)
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says - Alkermes ( NASDAQ:ALKS )
On Tuesday, Alkermes plc ALKS revealed topline results from the narcolepsy type 2 ( NT2 ) and idiopathic hypersomnia ( IH ) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680 for narcolepsy.
In Article Trend: Somewhat-Bullish
April 2, 2024 (16:10) / "Zacks Commentary" (by Zacks Equity Research)
Why Alkermes ( ALKS ) is Poised to Beat Earnings Estimates Again
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In Article Trend: Somewhat-Bullish
March 26, 2024 (11:00) / "GlobeNewswire" (by Inc.)
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company announces Q4 and YE 2023 financial results and provides business update.
In Article Trend: Neutral
March 26, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Invesco S&P SmallCap Health Care ETF ( PSCH ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In Article Trend: Bullish
March 25, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
In Article Trend: Somewhat-Bullish
March 20, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
In Article Trend: Somewhat-Bullish
March 15, 2024 (22:15) / "Zacks Commentary" (by Zacks Equity Research)
Alkermes ( ALKS ) Stock Moves -0.45%: What You Should Know
In the most recent trading session, Alkermes (ALKS) closed at $28.75, indicating a -0.45% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
March 15, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks With Rising Relative Strength: Intra-Cellular Therapies
On Friday, Intra-Cellular Therapies ( ITCI ) got an upgrade to its Relative Strength ( RS ) Rating, from 68 to 71. X IBD's unique rating measures share price action with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
March 14, 2024 (14:24) / "Zacks Commentary" (by Zacks Equity Research)
Envista ( NVST ) Faces Macroeconomic Challenges, FX Headwind
The challenging macroeconomic conditions are resulting in a significant escalation in Envista's (NVST) costs and expenses.
In Article Trend: Somewhat-Bullish
March 13, 2024 (16:45) / "Zacks Commentary" (by Zacks Equity Research)
3 Reasons Why Alkermes ( ALKS ) Is a Great Growth Stock
Alkermes (ALKS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
In Article Trend: Bullish
March 12, 2024 (13:50) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Alkermes ( ALKS ) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In Article Trend: Bullish
March 11, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Insmed Shows Market Leadership With Jump To 81 RS Rating
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Insmed ( INSM ) cleared that benchmark Monday, with a jump from 78 to 81 Monday.
In Article Trend: Somewhat-Bullish
March 11, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Arrowhead Pharm Shows Market Leadership With Jump To 83 RS Rating
On Monday, Arrowhead Pharm ( ARWR ) cleared a key performance benchmark, with its Relative Strength ( RS ) Rating rising into the 80-plus percentile with an upgrade to 83, up from 80 the day before.
In Article Trend: Somewhat-Bullish
March 8, 2024 (14:45) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Alkermes ( ALKS ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In Article Trend: Somewhat-Bullish
March 8, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Alkermes ( ALKS ) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In Article Trend: Somewhat-Bullish
March 7, 2024 (23:15) / "Zacks Commentary" (by Zacks Equity Research)
Why Alkermes ( ALKS ) Outpaced the Stock Market Today
Alkermes (ALKS) concluded the recent trading session at $29.45, signifying a +1.76% move from its prior day's close.
In Article Trend: Somewhat-Bullish
March 7, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Revolution Medicines Scores Relative Strength Rating Upgrade; Hits Key Benchmark
Revolution Medicines Scores Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 6, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Halozyme Therapeutics Joins Rank Of Stocks With 95-Plus Composite Rating
On Wednesday, Halozyme Therapeutics ( HALO ) got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. X The new rating is a sign the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria.
In Article Trend: Bullish
March 5, 2024 (18:50) / "Investors Business Daily" (by JULIE MAK)
Amicus Therapeutics Stock Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics ( FOLD ) stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. This proprietary rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
In Article Trend: Somewhat-Bullish
March 5, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Avadel Pharm ADR Scores Relative Strength Rating Upgrade; Hits Key Benchmark
Avadel Pharm ADR Scores Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Amicus Therapeutics Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics ( FOLD ) saw its Relative Strength Rating rise from 69 to 74 on Tuesday. X This proprietary rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
In Article Trend: Somewhat-Bullish
March 1, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Composite Rating For Catalyst Pharmaceuticals Rises To 97
Catalyst Pharmaceuticals ( CPRX ) saw an improvement in its IBD SmartSelect Composite Rating Friday, from 94 to 97. X The new rating is a sign the stock is outpacing 97% of all stocks when it comes to the most important stock-picking criteria.
In Article Trend: Somewhat-Bullish
February 29, 2024 (23:15) / "Zacks Commentary" (by Zacks Equity Research)
Alkermes ( ALKS ) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Alkermes (ALKS) stood at $29.69, denoting a -0.37% change from the preceding trading day.
In Article Trend: Somewhat-Bullish
February 29, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Stock Upgrades: Madrigal Pharmaceuticals Shows Rising Relative Strength
In a welcome move, Madrigal Pharmaceuticals ( MDGL ) saw its Relative Strength Rating rise from 69 to 78 on Thursday. When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.
In Article Trend: Bullish
February 28, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Beam Therapeutics Scores Relative Strength Rating Upgrade
Beam Therapeutics ( BEAM ) had its Relative Strength ( RS ) Rating upgraded from 81 to 94 Wednesday. X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength. This exclusive rating from Investor's Business Daily measures price movement with a ...
In Article Trend: Bullish
February 28, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Janux Therapeutics Scores Relative Strength Rating Upgrade
Janux Therapeutics ( JANX ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an upgrade from 89 to 99. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
In Article Trend: Bullish
February 28, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Stocks Showing Market Leadership: Ligand Pharmaceuticals Earns 92 RS Rating
On Wednesday, Ligand Pharmaceuticals ( LGND ) got an upgrade to its Relative Strength ( RS ) Rating, from 73 to 92. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
In Article Trend: Bullish
February 28, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks To Watch: Biomea Fusion Sees Relative Strength Rating Rise To 92
Biomea Fusion ( BMEA ) saw a positive improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 86 to 92. X When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.
In Article Trend: Bullish
February 28, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Structure Therap ADR Scores Relative Strength Rating Upgrade; Hits Key Threshold
Structure Therap ADR Scores Relative Strength Rating Upgrade. Hits Key Threshold Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
February 27, 2024 (19:57) / "Investors Business Daily" (by Investor's Business Daily)
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Beam Therapeutics ( BEAM ) stock saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, with an upgrade from 73 to 81. The Cambridge, Mass.-biotech company reported strong Q4 and full year 2023 results and reiterated milestones across the company's sickle cell disease and ...
In Article Trend: Bullish
February 27, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Biomea Fusion Scores Relative Strength Rating Upgrade; Hits Key Threshold
Biomea Fusion Scores Relative Strength Rating Upgrade. Hits Key Threshold Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
February 27, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Beam Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating
Beam Therapeutics ( BEAM ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, with an upgrade from 73 to 81. X When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.
In Article Trend: Bullish
February 27, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks Generating Improved Relative Strength: Arcus Biosciences
Arcus Biosciences ( RCUS ) had its Relative Strength ( RS ) Rating upgraded from 70 to 73 Tuesday -- a welcome improvement, but still below the 80 or higher score you prefer to see. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
In Article Trend: Bullish
February 27, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade
The Relative Strength ( RS ) Rating for ACADIA Pharmaceuticals ( ACAD ) jumped into a new percentile Tuesday, as it got a lift from 61 to 71. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
In Article Trend: Somewhat-Bullish
February 27, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Celldex Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90
On Tuesday, Celldex Therapeutics ( CLDX ) got an upgrade to its Relative Strength ( RS ) Rating, from 84 to 95. X When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.
In Article Trend: Somewhat-Bullish
February 27, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Krystal Biotech Joins Rank Of Stocks With RS Ratings Over 90
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Krystal Biotech ( KRYS ) , which saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, rising from 61 to 95.
In Article Trend: Bullish
February 26, 2024 (13:50) / "Zacks Commentary" (by Zacks Equity Research)
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
In Article Trend: Bullish
February 26, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
Beam Therapeutics Earns RS Rating Upgrade
On Monday, Beam Therapeutics ( BEAM ) got a positive adjustment to its Relative Strength ( RS ) Rating, from 70 to 73. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
In Article Trend: Bullish
February 25, 2024 (07:48) / "Stocknews.com" (by Defense World Staff)
Alkermes ( NASDAQ:ALKS ) Rating Lowered to Buy at StockNews.com
Alkermes ( NASDAQ:ALKS - Get Free Report ) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a report released on Friday. ALKS has been the subject of a number of other research reports.
In Article Trend: Somewhat-Bullish
February 23, 2024 (15:45) / "Investors Business Daily" (by Investor's Business Daily)
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals Stock Earns RS Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
In Article Trend: Bullish
February 23, 2024 (14:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Alkermes ( ALKS ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In Article Trend: Somewhat-Bullish
February 23, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Agios Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals Earns Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...
In Article Trend: Bullish
February 23, 2024 (07:18) / "Stocknews.com" (by Defense World Staff)
Alkermes ( NASDAQ:ALKS ) Downgraded by StockNews.com to Buy
Alkermes ( NASDAQ:ALKS - Get Free Report ) was downgraded by StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Friday. Several other equities analysts also recently commented on the stock.
In Article Trend: Somewhat-Bullish
February 22, 2024 (20:30) / "Motley Fool" (by Motley Fool Transcribing)
Harmony Biosciences ( HRMY ) Q4 2023 Earnings Call Transcript
HRMY earnings call for the period ending December 31, 2023.
In Article Trend: Somewhat-Bullish
February 22, 2024 (08:00) / "Investors Business Daily" (by Investor's Business Daily)
Stocks Showing Improving Market Leadership: Ultragenyx Pharm Earns 81 RS Rating
The Relative Strength ( RS ) Rating for Ultragenyx Pharm ( RARE ) jumped into a new percentile Thursday, with an increase from 78 to 81. X When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.
In Article Trend: Bullish
February 21, 2024 (14:45) / "Zacks Commentary" (by Zacks Equity Research)
Why Alkermes ( ALKS ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In Article Trend: Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website